Article Text

PDF
Proteins of the mitotic checkpoint and spindle are related to chromosomal instability and unfavourable prognosis in patients with myelodysplastic syndrome
  1. Kelly Roveran Genga1,
  2. Francisco Dário Rocha Filho2,
  3. Francisco Valdeci de Almeida Ferreira2,
  4. Juliana Cordeiro de Sousa3,
  5. Fernando Sergio Studart4,
  6. Silvia Maria Meira Magalhães3,5,
  7. Fabíola Fernandes Heredia1,
  8. Ronald Feitosa Pinheiro1,3,5
  1. 1Department of Pathology, Post-Graduate Program in Pathology, Federal University of Ceará, Fortaleza, Ceará, Brazil
  2. 2Department of Pathology, Federal University of Ceará, Fortaleza, Ceará, Brazil
  3. 3Laboratory Cytogenomic of Cancer, Federal University of Ceará, Fortaleza, Ceará, Brazil
  4. 4University of Fortaleza, Fortaleza, Ceará, Brazil
  5. 5Department of Clinical Medicine, Post-Graduate Program in Medical Sciences, Federal University of Ceará, Fortaleza, Ceará, Brazil
  1. Correspondence to Dr Ronald Feitosa Pinheiro, Department of Pathology, Post-Graduate Program in Pathology, Federal University of Ceará, R. Pereira Valente, 738, Meireles, Fortaleza, Ceará 60160-250, Brazil; ronaldpinheiro{at}pq.cnpq.br, ronaldfpinheiro{at}uol.com.br

Abstract

Aims To study the immunoexpression of proteins related to the mitotic checkpoint (cell division cycle 20 (CDC20), mitotic arrest deficient 2 (MAD2)) and the mitotic spindle (Aurora-B) in patients with myelodysplastic syndrome (MDS).

Methods Protein expression was analysed in bone marrow tissue samples from 40 patients with MDS using immunohistochemistry. Prognostic markers (transfusion dependency, depth of cytopenias, chromosomal abnormalities and survival) were also studied.

Results Higher MAD2 expression was observed among patients with platelets <50×109/L than among patients with platelets ≥50×109/L (42.6±22.8% vs 22.7±19.1%, respectively). Higher CDC20 expression was identified among patients with three dysplasias compared with patients who presented with one or two dysplasias (33.9±24.1% vs 10.5±5.7% vs 12.8±7.8%, respectively), among patients who exhibited a complex versus non-complex karyotype (50.0±30.2% vs 18.4±14%, respectively) and among patients with platelets <50×109/L vs platelets ≥50×109/L (38.2±26.2% vs 16.1±12.4%, respectively). Higher Aurora-B expression was found in patients with an abnormal versus normal karyotype (21.2±13.2% vs 7.5±5.0%, respectively). High expression of MAD2 and CDC20 (≥50%) was associated with severe thrombocytopenia. We also found statistically significant differences in the overall survival rate when comparing different degrees of CDC20, MAD2 and Aurora-B protein expression.

Conclusions To the best of our knowledge, this is the first report to demonstrate that these proteins are associated with chromosomal abnormalities and poor prognosis in patients with MDS.

  • MYELODYSPLASIA
  • HEMATOPATHOLOGY
  • IMMUNOHISTOCHEMISTRY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.